Forum: Financial Investment Forum. - Discuss Stocks, Cryptocurrency, And Other Financial Investments

Thread: Read if you want one stock you can retire on

Page 6 of 8 FirstFirst 12345678 LastLast
  1. #126  
    Everybody Got Dey Cups But Dey Ain't Chipped In.... RapStar's Avatar
    Join Date
    Dec 2004
    Location
    West Palm
    Posts
    714
    Quote Originally Posted by MattyMatt View Post
    Took it 2 weeks...lol Ready, BOOM!

    Those extra few thousand I picked up avg $3.28 are already sitting pretty just as expected...
    Well played, that's about where I first got in as well.
    Reply With Quote  
     

  2. #127  
    RX Junior brucefan's Avatar
    Join Date
    Jan 2005
    Location
    wellington
    Posts
    2,597
    BOXER UPDATE ON PRED

    TARGET 6.5, EVENTUALLY 7, 8

    https://www.thetechtrader.com/charts...m_campaign=COD
    PLAN, PRED (03:40)
    Reply With Quote  
     

  3. #128  
    RX Junior brucefan's Avatar
    Join Date
    Jan 2005
    Location
    wellington
    Posts
    2,597
    PRED ~ As you know we recommended PRED back in April 2019 @ 2.13 since that time the share price has exploded to the upside. The up-listing of the companies shares to the NASDAQ most likely will happen during the week of June 10th-17th 2019. Once this happens the floodgate of news pressers will saturate the business media channels. Earlier this week we sent out subscribers an alert telling them not to sell their shares. Since that time PRED shares have appreciated another $1.00! We believe that investor's should not be fooled or shaken out because the party is about to begin. Via the grapevine (we believe dependable info) the listing will happen. Major news announcements concerning partnerships/joint venture will be released propelling shares much higher. Brokerage firm introductions will be made with recommendations. Since shares will trade on NASDAQ every Institution, hedge fund, Index and Mutual Fund will have access to purchase shares. A major Stem Cell conference is happening June 23rd which will also expose the work that they are doing within the field.
    Their Endo product is nearing nationwide and most likely international sales. Yours truly william Velmer editor ( since 1984) http://www.saadvisory.com If is our belief that next week we could sell shares approaching $7-$10/sh. It all sounds to good to be true, but Unicorns do exist. PRED~ strong buy recommendation continues. Do not sell! It is like getting off the train and it then leaves you at the station. Read our complete recommedations via http://www.saadvisory.com April 22nd and April 29th 2019
    Reply With Quote  
     

  4. #129  
    Everybody Got Dey Cups But Dey Ain't Chipped In.... RapStar's Avatar
    Join Date
    Dec 2004
    Location
    West Palm
    Posts
    714
    Quote Originally Posted by brucefan View Post
    PRED ~ As you know we recommended PRED back in April 2019 @ 2.13 since that time the share price has exploded to the upside. The up-listing of the companies shares to the NASDAQ most likely will happen during the week of June 10th-17th 2019. Once this happens the floodgate of news pressers will saturate the business media channels. Earlier this week we sent out subscribers an alert telling them not to sell their shares. Since that time PRED shares have appreciated another $1.00! We believe that investor's should not be fooled or shaken out because the party is about to begin. Via the grapevine (we believe dependable info) the listing will happen. Major news announcements concerning partnerships/joint venture will be released propelling shares much higher. Brokerage firm introductions will be made with recommendations. Since shares will trade on NASDAQ every Institution, hedge fund, Index and Mutual Fund will have access to purchase shares. A major Stem Cell conference is happening June 23rd which will also expose the work that they are doing within the field.
    Their Endo product is nearing nationwide and most likely international sales. Yours truly william Velmer editor ( since 1984) http://www.saadvisory.com If is our belief that next week we could sell shares approaching $7-$10/sh. It all sounds to good to be true, but Unicorns do exist. PRED~ strong buy recommendation continues. Do not sell! It is like getting off the train and it then leaves you at the station. Read our complete recommedations via http://www.saadvisory.com April 22nd and April 29th 2019
    Thanks for sharing, Bruce. I added this AM at the open after closing a quick trade and boy am I glad I did. What a run today!
    Reply With Quote  
     

  5. #130  
    RX Junior brucefan's Avatar
    Join Date
    Jan 2005
    Location
    wellington
    Posts
    2,597
    lets hope hes right


    DAMS Consulting (@DAMSConsulting)
    6/8/19, 9:52 AM
    $PRED I have the data on naked shorts in this name From ⁦‪@buyinsnet‬⁩ Total naked short is 36,000,000M on Total vol of 83M AVG PRICE of short is $1.97(dead) They have sold about $71M worth of Counterfeit shares
    LONGS you have a RAT trapped Big time (FACTS) follow him does good work
    Reply With Quote  
     

  6. #131  
    RX Wizard MattyMatt's Avatar
    Join Date
    Jan 2010
    Location
    Dirty South
    Posts
    14,989
    Let’s F’n Roll! Added 1k more @ $5.60 on Friday. I’m all tapped out now and ready to ride...
    Reply With Quote  
     

  7. #132  
    RX Local
    Join Date
    Jul 2007
    Location
    Boston
    Posts
    23,798
    Nice call Bruce....O/T but how quick you think it takes fed to get back to 0? End 2020?
    Reply With Quote  
     

  8. #133  
    RX Junior
    Join Date
    Nov 2009
    Location
    Smyrna, Georgia
    Posts
    1,042
    I made really nice returns with GDEN and ERI on Bruce’s recommendations. I have been watching PRED ascend, but all along I kept thinking I didn’t buy it at $1.12, why should I buy it at $1.77; I didn’t buy it at $3.60, why should I buy it at $4.20... etc., etc. May I humbly ask the question if PRED is still a good buy?
    Reply With Quote  
     

  9. #134  
    RX Junior brucefan's Avatar
    Join Date
    Jan 2005
    Location
    wellington
    Posts
    2,597
    Quote Originally Posted by fballgenius View Post
    I made really nice returns with GDEN and ERI on Bruce’s recommendations. I have been watching PRED ascend, but all along I kept thinking I didn’t buy it at $1.12, why should I buy it at $1.77; I didn’t buy it at $3.60, why should I buy it at $4.20... etc., etc. May I humbly ask the question if PRED is still a good buy?
    The title of this thread should give you all the information you need to answer that question

    This stock hasn't started yet . You need to realize how many people CANT buy until its on NASDQ, and how much information will come out once they uplist

    My opinion is I think if you dont buy this stock, you may regret it for the rest of your life

    One year ago my target was 10, and I still feel very good about that one, so could I be right about my long term target?
    Reply With Quote  
     

  10. #135  
    RX Junior brucefan's Avatar
    Join Date
    Jan 2005
    Location
    wellington
    Posts
    2,597
    ByJim BloomPosted on June 10, 2019 SHARE TWEET SHARE EMAIL COMMENTS
    Predictive Technology Group Inc (OTCMKTS: PRED) is flying higher after reporting a tenth consecutive quarter of revenue growth. The Company achieving significant progress in the building of a strong infrastructure for supporting development and commercialization of genetic-based diagnostics also continues to excite investors, consequently fuelling the upswing.


    Predictive Technology Group Price Analysis


    A 200% plus spike since the start of the year affirms renewed investor interest after the underperformance of the past year. The spike has since catapulted the stock to all-time highs with the upward momentum showing no signs of slowing down.


    Pullbacks have so far presented entry positions from where bulls have come in and continued to push the stock up. As it stands, support on pullbacks, from current highs, is seen at the $3.20 level from where the stock commenced the current leg higher.




    PRED Daily Chart


    Above the critical support level, Predictive Technology Group remains supported for further upside action on minor corrections. Conversely, a breach of the support level could elicit some pressure, downwards, which could result in the stock plunging back to the $2 level, the next substantial support level.


    In our view, Predictive Technology Group is likely to continue climbing the ladder as the upward momentum continues to gather pace.


    What Does Predictive Technology Group Do?


    Predictive Technology Group is engaged in the development and commercialization of discoveries and technologies for novel molecular diagnostics and pharmaceutical therapeutic human cells. The Company offers ARTguide, a genetic diagnostic and prognostic test for women struggling with endometriosis.






    Revenue Growth Milestone


    Predictive Technology Group strong price performance in recent weeks is in response to investor’s reaction to an impressive earnings report that signifies underlying growth. The company reporting revenues of $11.3 million, representing a 167% increase marked the tenth consecutive quarter, of sequential revenue growth.


    Revenue for the nine months ended March 31, 2019, were up 217%, exceeding the $30 million mark. The company has since seen its cash flow from operations exceed the $ 3.1 million as the race for shareholder value continues to gather pace.


    Predictive Technology Group has also achieved a significant milestone that positions it for accelerated growth going forward. For starters, the Company is currently operating from a state of the art production laboratory and R&D facility.


    “We also finalized the integration of Taueret Laboratories and Inception Dax into Predictive Laboratories, providing us with a CAP/CLIA-accredited laboratory for processing our genetic-based tests. We strengthened our Board with the appointment of independent directors with exceptional industry, public affairs, financial and governance experience,” stated CEO Bradley Robinson.


    Clinical Studies Progress


    The future looks bright for Predictive Technology Group after yet another stellar performance in the third quarter. Clinical studies are progressing well, pointing to what could end up being a record year on revenue generation as well as operational efficiency.


    The Company has already reached an enrollment milestone of 200 participants as part of an ongoing Institutional Review Board of the spine and joint disease, leading to chronic pain. The primary objective of the study is to conduct genetic research on the diagnosis, treatment, and prevention of conditions causing chronic pain.


    In addition, the Company has signed a letter of intent with IQVIA through its wholly owned subsidiary Predictive Biotech as it seeks to commence clinical trials for Osteoarthritis of the knee. The two are joining forces to accelerate the process of identifying and executing appropriate regulatory pathways for existing products and future product candidates.


    “This OA of the knee study is the first of several trials that Predictive Biotech intends to conduct for our cellular therapy injectable products. We are excited to leverage IQVIA’s expertise as we expand our focus from human cell and tissue products (HCT/Ps) into the biopharmaceutical market,” said Predictive Biotech CEO Eric Olson.


    Bottom Line


    Predictive Technology Group has risen an impressive 200% in 2019 in what is turning out to be a break out year. The spike comes on investors taking note of the company’s revenue run rate as well as the progress made on the development of precision therapeutic treatments targeting various conditions.


    A spike in share price has left the Company well positioned to secure NASDAQ listing that would mark a significant milestone as part of the growth strategy. As it stands, the stock looks set to continue powering higher as underlying developments and fundamentals continue to strengthen investor confidence.


    In our view, pullbacks should provide exciting entry positions, for buying the stock at a discount, pending further upside action.


    We will be updating our subscribers as soon as we know more. For the latest updates on PRED, sign up below!


    Disclosure: We have no position in PRED and have not been compensated for this article. https://insiderfinancial.com/predict...n-dips/179197/
    Reply With Quote  
     

  11. #136  
    RX Wizard MattyMatt's Avatar
    Join Date
    Jan 2010
    Location
    Dirty South
    Posts
    14,989
    Quote Originally Posted by fballgenius View Post
    I made really nice returns with GDEN and ERI on Bruce’s recommendations. I have been watching PRED ascend, but all along I kept thinking I didn’t buy it at $1.12, why should I buy it at $1.77; I didn’t buy it at $3.60, why should I buy it at $4.20... etc., etc. May I humbly ask the question if PRED is still a good buy?
    I'm still buying, and have been at every price you listed, even cheaper at $.88. What a ride, but, I too, think we're just getting started. She's showing zero signs of resistance...
    Reply With Quote  
     

  12. #137  
    RX Semi-God
    Join Date
    May 2007
    Location
    Unknown
    Posts
    34,243
    Quote Originally Posted by MattyMatt View Post
    I'm still buying, and have been at every price you listed, even cheaper at $.88. What a ride, but, I too, think we're just getting started. She's showing zero signs of resistance...
    Your mailbox is full. Can you clear?
    Welchers are the worst.
    Reply With Quote  
     

  13. #138  
    RX Wizard MattyMatt's Avatar
    Join Date
    Jan 2010
    Location
    Dirty South
    Posts
    14,989
    Quote Originally Posted by Enfuego View Post
    Your mailbox is full. Can you clear?
    Done
    Reply With Quote  
     

  14. #139  
    RX Wizard MattyMatt's Avatar
    Join Date
    Jan 2010
    Location
    Dirty South
    Posts
    14,989
    Still as strong as ever... Drop back to $5.90 screamed Buy, Buy, Buy, so I did for a little, lol

    Basically a 1M shares traded again on another Green Day. Still plenty to love here...
    Reply With Quote  
     

  15. #140  
    RX Junior brucefan's Avatar
    Join Date
    Jan 2005
    Location
    wellington
    Posts
    2,597
    https://s1.q4cdn.com/460208960/files...ndermosten.pdf

    ZACKS INITIATES COVERAGE. 8 current valuation
    Reply With Quote  
     

  16. #141  
    RX Wizard MattyMatt's Avatar
    Join Date
    Jan 2010
    Location
    Dirty South
    Posts
    14,989
    Looks like $5.90 was the new floor. Tested it again today, instant bounceback. She's as strong as ever...
    Reply With Quote  
     

  17. #142  
    RX Junior brucefan's Avatar
    Join Date
    Jan 2005
    Location
    wellington
    Posts
    2,597
    Quote Originally Posted by MattyMatt View Post
    Looks like $5.90 was the new floor. Tested it again today, instant bounceback. She's as strong as ever...
    Pullback in an uptrend suck , but part of the game . Lets have some fun. Guesses for the closing price the end of June

    Ill go first . 9.65
    Reply With Quote  
     

  18. #143  
    RX Wizard MattyMatt's Avatar
    Join Date
    Jan 2010
    Location
    Dirty South
    Posts
    14,989
    Quote Originally Posted by brucefan View Post
    Pullback in an uptrend suck , but part of the game . Lets have some fun. Guesses for the closing price the end of June

    Ill go first . 9.65
    $9.26 (staying under $10 so it has a chance to go there...lol)
    Reply With Quote  
     

  19. #144  
    Everybody Got Dey Cups But Dey Ain't Chipped In.... RapStar's Avatar
    Join Date
    Dec 2004
    Location
    West Palm
    Posts
    714
    Quote Originally Posted by brucefan View Post
    Pullback in an uptrend suck , but part of the game . Lets have some fun. Guesses for the closing price the end of June

    Ill go first . 9.65
    Part of the process. It won't always be green. Learned this long ago.

    I'll go with a Price is Right style Guess of $9.66 !
    Reply With Quote  
     

  20. #145  
    RX Junior brucefan's Avatar
    Join Date
    Jan 2005
    Location
    wellington
    Posts
    2,597
    Chairman is also a high-level director at Pfizer

    Too many potential catalysts to list in our first report

    Welcome to the world of regenerative medicine

    Good day everyone,

    Today we are initiating coverage of Predictive Technology Group, Inc. (OTC: PRED), a company that aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics and companion therapeutics.

    Through its subsidiaries, Predictive Therapeutics, Predictive Biotech, and Predictive Laboratories, the company is focused on endometriosis, scoliosis, degenerative disc disease, and human cell and tissue products.

    The subsidiaries use genetic and other information in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases.

    Current price $4.50 per share

    The company has completed the application and submitted the request to list Predictive on The NASDAQ Exchange. The NASDAQ listing remains subject to the approval of NASDAQ and the satisfaction of all NASDAQ listing standards.

    As at the end of Q3 (March 31, 2019), nine-month revenue increased 217% to $30 million with $3.1 million in positive cash flow from operations.

    Q3 marks the company’s 10th consecutive quarter of sequential growth in revenue.

    PRED seems to have and endless stream of catalysts and milestones fueling its rising stock price and here are a few of them:


    Recent Corporate Developments
    Integrated the sales and marketing team from FlagshipHealth Group, to support commercial activities for Predictive Biotech and Predictive Laboratories.

    Named Sen. Orrin G. Hatch, Ronald Barhorst and Jay M. Moyes to its Board of Directors, expanding its Board to six including four independent directors.

    Mr. John E. Sorrentino Chairman of Predictive Technology Group, Inc. is also Vice-President and Chief Operating Officer of Vaccine Research and Development at Pfizer and has vast experience in R&D and clinical laboratory management.

    Recent Predictive Laboratories Developments
    Completed the acquisition of Taueret Laboratories, LLC, a provider of genetic testing and DNA analysis services through its CAP/CLIA-certified laboratory.

    Integrated over $5 million of recently purchased new genomics equipment and supplies into laboratory to expand the technical capabilities and capacities.

    Launched ARTguide™ genetic test for reproductive endocrinologists into 14 Key Opinion Leader (KOL) clinics to refine the test ordering and reporting processes.

    Presented a poster titled The Genetic Architecture of Endometriosis at the Society for Reproductive Investigation (SRI) meeting.

    Recent Predictive Biotech Developments
    Reported 10th consecutive quarter-over-quarter revenue growth.

    Completed buildout of a new 22,000-square-foot production laboratory and R&D facility meeting good manufacturing Practice (GMP) and Good Tissue Practice (GTP) requirements.

    Predictive Biotech’s products are FDA-compliant and sourced from the rich Wharton’s Jelly layer of the umbilical cord and amniotic fluid and amnio tissue from healthy, full-term donors.

    Last month signed letter of intent with IQVIA (Formerly Quintiles and IMS) to guide the regulatory FDA process for potential drugs beginning with CoreCyte™ for osteoarthritis (OA) of the knee.

    Conclusions:

    We believe the anticipated uplist to the NASDAQ may send PRED shares soaring. Many institutions and funds are precluded from investments in OTC companies. A NASDAQ listing could open the floodgates for those types of investors.

    There is an increasing demand for the company’s human cell and tissue products.

    Gross profit margin for first nine months of fiscal 2019 was 63.8%.

    Cash provided by operating activities for or the nine months ended March 31, 2019 was $3.1 million.

    Senator Orrin Hatch lends a great deal of credibility to the company’s board.

    PRED shares have been moving up all year, but have taken a breather in the past few trading days, creating what we feel, could be a buying opportunity.

    There are so many catalysts and milestones happening at PRED we’ve dedicated this newsletter primarily to them. Look for our update tomorrow when we discuss Predictive’s amazing technologies, products and future in more detail.


    The Team
    Reply With Quote  
     

  21. #146  
    RX Wizard MattyMatt's Avatar
    Join Date
    Jan 2010
    Location
    Dirty South
    Posts
    14,989
    Still here, holding all shares strong. Can't shake me, hell, I wish I had more free cash to scoop up some more cheapies the past few days...Ugh
    Reply With Quote  
     

  22. #147  
    RX Member
    Join Date
    Dec 2007
    Location
    Los angeles
    Posts
    85
    Quote Originally Posted by brucefan View Post
    The title of this thread should give you all the information you need to answer that question

    This stock hasn't started yet . You need to realize how many people CANT buy until its on NASDQ, and how much information will come out once they uplist

    My opinion is I think if you dont buy this stock, you may regret it for the rest of your life

    One year ago my target was 10, and I still feel very good about that one, so could I be right about my long term target?

    The key is "Can't buy until it's on the NASDQ"
    Very true, so many funds and managers can't touch a Pink sheet stock.

    I like it.
    Reply With Quote  
     

  23. #148  
    RX Junior brucefan's Avatar
    Join Date
    Jan 2005
    Location
    wellington
    Posts
    2,597
    Thermo Fisher Scientific and Predictive Laboratories Announce Global Infertility Research Collaboration





    PR NewswireJune 19, 2019


    Studies aim to elucidate infertility genetics for development of noninvasive test to support decision making and improved outcomes for women pursuing fertility treatment


    CARLSBAD, Calif., June 19, 2019 /PRNewswire/ -- Thermo Fisher Scientific announced today that it has entered into a global research collaboration with Predictive Laboratories, a wholly owned subsidiary of Predictive Technology Group, Inc., (OTC PINK: PRED) focused on studying the genetic factors underlying infertility in women. The work will utilize Thermo Fisher's various offerings for reproductive health, including Applied Biosystems CarrierScan Assay, Ion ReproSeq PGS Assay, CytoScan Dx Assay, and Ion AmpliSeq Exome RDY for whole exome sequencing.
    Infertility has many potential causes, which may involve one or both partners. In some cases, no cause of the condition can be determined, leading the infertility to be described as "unexplained." The most common causes among women are irregular ovulation, blockage of the fallopian tubes, and endometriosis. The American College of Obstetrics and Gynecology (ACOG) reports that at least 40 percent of women with infertility have endometriosis.
    Endometriosis occurs when the endometrial tissue that lines the uterine wall grows in other areas of the body outside of the uterus. While the symptoms are well-characterized, including pelvic pain, heavy periods, and pain during sexual intercourse or bowel movements, the disease is highly variable and many women have asymptomatic endometriosis, which has a significant impact on their fertility. The studies with Predictive Laboratories aim to elucidate the genetic basis of this condition, which is expected to more accurately define which women will experience infertility.
    "Infertility among women who seek to conceive has become an increasingly common condition, which leads to much frustration and financial burden as they seek alternative solutions," said Bradley Robinson, CEO of Predictive Technology Group. "Our collaboration with Thermo Fisher brings together our innovative research and development capabilities with market-leading next generation sequencing technology to better understand the genetics of infertility for future development of a diagnostic solution."
    Worldwide, around 70 to 80 million couples currently experience infertility, which causes significant depression, anxiety, and loss of work productivity. The ability to identify women who will experience trouble conceiving will allow for early intervention and personalized treatment planning that may result in fewer cycles to achieve a successful pregnancy.
    "We look forward to this exciting and important work with Predictive Laboratories to better understand infertility in women," said Yan Zhang, general manager, reproductive health at Thermo Fisher. "With the combination of our partner's expertise and our advanced solutions for genetic analysis, we are committed to reducing the future financial and emotional burden couples face while undergoing fertility treatment."
    About Thermo Fisher Scientific
    Thermo Fisher Scientific Inc. is the world leader in serving science, with revenues of more than $24 billion and approximately 70,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to market and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive services. For more information, please visit www.thermofisher.com.
    About Predictive Technology Group, Inc.
    Predictive Technology Group aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics and companion therapeutics through its subsidiaries Predictive Therapeutics, Predictive Biotech, and Predictive Laboratories. These subsidiaries are focused on endometriosis, scoliosis, degenerative disc disease and human cell and tissue products. The subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person's risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively. Additional information is available at Predtechgroup.com; Predrx.com; Predictivebiotech.com; and Predictivelabs.com.

    Media Contact Information:
    Mauricio Minotta
    Director, Public Relations
    +1 760 929 2456
    Mauricio.minotta@thermofisher.com

    Mamie Reeder
    Predictive Technology Group, Inc.
    385-297-8067
    mreeder@predtechgroup.com

    Reply With Quote  
     

  24. #149  
    RX Wizard MattyMatt's Avatar
    Join Date
    Jan 2010
    Location
    Dirty South
    Posts
    14,989
    Hellz Yea!
    Reply With Quote  
     

  25. #150  
    RX Junior brucefan's Avatar
    Join Date
    Jan 2005
    Location
    wellington
    Posts
    2,597
    Biotech Company Growing Revenues, Seeking NASDAQ Listing

    PRED is bringing the future of medicine to the present

    Good day everyone,

    We are continuing our coverage of Predictive Technology Group, Inc. (OTC: PRED), a company that aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics and companion therapeutics.

    PRED shares have had a tremendous spring. Trading under $2.00 per share in March and jumping to over $6.00 recently. The past few trading sessions have seen the share price soften as traders take some well-deserved profits. This share price consolidation has created a potential opportunity for our members. The catalysts and financial metrics that drove the PRED shares higher are not only still in place, but getting better. Do your due diligence and pick an entry level.

    PRED currently derives the majority of its revenues (exceeding $10 million per quarter) from the cellular therapy division that provides products derived from amniotic tissue and Wharton’s Jelly that are used by physicians in a variety of healing applications. The company is not required to conduct clinical trials for its cellular therapy products because they do not make efficacy claims.

    To facilitate revenue growth, the company may focus efforts on obtaining FDA approval for its suite of diagnostic tests and allogenic cell products. They could also become a supplier of cellular products to strategic partners in areas such as oncology and orthobiologics as well as a provider of inventory to tissue banks.

    Predictive also intends to bring drugs to the market. Last month the company signed letter of intent with IQVIA (Formerly Quintiles and IMS) to guide the regulatory FDA process for potential drugs beginning with CoreCyte™ for osteoarthritis of the knee.

    Also last month, the company announced that Predictive Laboratories has reached an enrollment milestone of 200 participants in its ongoing Institutional Review Board (IRB)-approved study of spine and joint disease leading to chronic pain. It’s possible this study could lead to a reduction in the use of opioids.

    The company’s substantial cash flow ($3.1 million last quarter) can help to facilitate the development of new products that require clinical trials.

    PRED has a proprietary genealogy database with over 30 million individuals and greater than 300,000 DNA samples, a valuable resource that can isolate genes that are implicated in disease and generate tests that are highly accurate.

    PRED has articulated a growth plan for each of its four segments. Predictive Biotech will continue with cellular therapy products, which do not make any efficacy claims while Predictive Therapeutics will pursue products that require review and approval from the FDA. CellSure will focus on procurement of tissue, optimizing cell yields and quality and offering storage services for new mothers. Predictive Laboratories, created through the acquisition of Taueret, will continue to develop and commercialize genetic diagnostic tests.

    Predictive’s marketing efforts in cellular therapy consists of over 20 sales team members and over 75 distributors that will target the naturopathic physicians, chiropractors, orthopedists, anti-aging, and cosmetic medicine and other specialties. The sales team, formerly consultants at Predictive, have only been employees for a couple of months.

    Predictive’s products include:
    AmnioCyte is a minimally manipulated human tissue allograft derived from amniotic fluid.

    AmnioCyte Plus is a minimally manipulated human tissue allograft derived from the extracellular matrix of the amniotic membrane.

    PolyCyte is a minimally manipulated human tissue allograft derived from the Wharton’s jelly of the umbilical cord.

    CoreCyte is a minimally manipulated human tissue allograft derived from the Wharton’s jelly of the umbilical cord.

    ARTguide is the first, non-invasive, integrated test for endometriosis and genetic causes of infertility.

    PG Plus helps healthcare providers prevent adverse drug reactions by providing genomic information.

    We believe the anticipated uplist to the NASDAQ may send PRED shares soaring. Many institutions and funds are precluded from investments in OTC companies. A NASDAQ listing could open the floodgates for those types of investors.

    There is increasing demand for the company’s human cell and tissue products.

    Gross profit margin for first nine months of fiscal 2019 was 63.8%.

    Cash provided by operating activities for or the nine months ended March 31, 2019 was $3.1 million.

    PRED has a fiscal year end of June 30th, so their Q4 and year end data will be forthcoming in the near term. If that data confirms the continuation of good financial results and corporate developments, it could act as a significant catalyst for the company’s shares.

    Senator Orrin Hatch lends a great deal of credibility to the company’s board. Hatch was one of 58 senators who signed a letter directed to President George W. Bush, requesting the relaxing of federal restrictions on embryonic stem cell research. In 2010, Hatch's bill was reauthorized which allowed stem cells from umbilical cords to be used to find treatment options.

    Predictive’s work with cellular therapy could have implications beyond the current scope of their operations. The technology is so new, we don’t yet know the possibilities, or the impact it could have on the treatment of many diseases.

    In the year 2000, science completed the mapping of the human genome and many thought “this is really going to change medicine down the road”. Here we go.

    Always bringing you the best under the radar stories in the small cap arena,

    The Team
    Reply With Quote  
     

Posting Permissions
  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts
  •